ICON Public (NASDAQ:ICLR) Price Target Lowered to $262.00 at Truist Financial

ICON Public (NASDAQ:ICLR) had its price target lowered by research analysts at Truist Financial from $284.00 to $262.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. Truist Financial’s price objective points to a potential upside of 41.47% from the stock’s previous close.

Several other equities analysts have also weighed in on ICLR. Robert W. Baird reduced their price objective on ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. William Blair reaffirmed an “outperform” rating on shares of ICON Public in a research report on Tuesday, January 14th. TD Cowen dropped their price objective on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Royal Bank of Canada reissued an “outperform” rating and issued a $263.00 target price on shares of ICON Public in a research note on Wednesday, January 15th. Finally, Barclays decreased their price target on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, ICON Public currently has a consensus rating of “Moderate Buy” and a consensus price target of $283.92.

ICON Public Trading Down 0.7 %

Shares of ICLR opened at $185.20 on Thursday. ICON Public has a twelve month low of $183.38 and a twelve month high of $347.72. The firm has a market capitalization of $15.28 billion, a P/E ratio of 20.65, a price-to-earnings-growth ratio of 1.78 and a beta of 1.19. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The stock’s fifty day simple moving average is $206.00 and its 200 day simple moving average is $251.32.

Hedge Funds Weigh In On ICON Public

Institutional investors have recently made changes to their positions in the business. Sierra Ocean LLC acquired a new stake in shares of ICON Public during the fourth quarter worth approximately $29,000. Park Place Capital Corp boosted its stake in ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 166 shares during the last quarter. Private Trust Co. NA grew its holdings in ICON Public by 48.8% during the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after acquiring an additional 82 shares in the last quarter. GAMMA Investing LLC increased its position in shares of ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares during the last quarter. Finally, Horizon Investments LLC raised its stake in shares of ICON Public by 534.0% in the 4th quarter. Horizon Investments LLC now owns 653 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 550 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.